OHB's €15.6 Billion European Satellite Program Tests Investor Patience

OHB's shares fall 4.6% despite a €1B IRIS² order, as technical overvaluation and profit-taking outweigh strong fundamentals.

The disconnect could hardly be starker. OHB has secured one of the largest contracts in its corporate history — a roughly €1 billion order to build 18 satellites for the medium-Earth orbit segment of Europe's IRIS² network, with the first spacecraft slated for operational readiness in 2029. Yet the market's response has been anything but celebratory. The shares closed Thursday at €229.50, down 4.6 percent on the day, after early gains from the IRIS² news were quickly surrendered.

That pattern has become uncomfortably familiar for the Bremen-based space group. Positive headlines have consistently failed to lift the stock in recent weeks. The shares have shed 3.2 percent since the half-year results and 11.4 percent since the SDAX index inclusion, with the IRIS² contract now extending that run of good news met by selling pressure.

A Rally That Outran Its Fundamentals

The technical picture helps explain the market's reticence. OHB's stock has more than tripled over the past twelve months, and even after the recent pullback it remains a formidable distance — 67 percent — below its 52-week high of €688.00. Tuesday's 5.65 percent decline was widely read as a textbook consolidation following a rally that had been fueled by the SDAX return and early IRIS² momentum, rather than a deterioration in the company's prospects.

With annualized volatility of 59 percent, OHB ranks among the most turbulent names in the SDAX, and the share price now sits roughly 18 percent beneath its 50-day moving average — a signal that short-term momentum has shifted. The stock is also approaching its 200-day average, a level that technicians will be watching closely. A decisive break below that marker could amplify selling pressure.

The Structural Story Remains Intact

Beneath the day-to-day noise, the strategic picture has arguably never been stronger. The overall IRIS² program carries a total volume of approximately €15.6 billion, and OHB is positioned as a major beneficiary. Notably, the competitive landscape is shifting in ways that favor the company: Airbus lost out on specific small-satellite sub-contracts to New Space players such as Aerospacelab, underscoring that OHB is on the right side of a reordering European space sector.

The IRIS² award is just one component of a growing order book. In July, OHB Italia secured the PRISMA Second Generation mission, which runs through the end of 2031. The first half of the year saw total output of €628 million, up from €470 million in the prior-year period — evidence that the operational momentum is real.

A Transformed Shareholder Base

The structural changes extend beyond the order book. A capital increase of €484 million was finalized just over a week ago, timed to coincide with OHB's unscheduled entry into the SDAX as a replacement for Klöckner & Co. The issuance of new shares, combined with the placement of holdings from the KKR vehicle Orchid Lux HoldCo, lifted the free float to roughly 18 percent. The Fuchs family retains a commanding majority stake of over 60 percent.

That combination — fresh capital for M&A and capacity expansion, coupled with a stable controlling shareholder — gives OHB the financial firepower to pursue growth without diluting its strategic direction. The larger free float should also improve liquidity and potentially broaden the institutional investor base.

Guidance Holds, Analysts See Upside

Management confirmed its full-year guidance at the end of July, projecting total output of €1.4 billion and an adjusted EBITDA margin between 10.5 and 11.0 percent. The half-year results showed the adjusted EBITDA margin up 30 percent year-on-year, lending credibility to those targets.

Analyst coverage has been broadly constructive. Jefferies' Chloe Lemarie issued a "Buy" rating in mid-August with a price target of €280, anticipating an acceleration in revenue and strong order intake, particularly in the defense segment from 2027 onward. Several other analysts initiated coverage in early August with price targets ranging from €250 to €360 — all above the current trading level.

The Valuation Question

The core debate for investors is whether the market is willing to sustain OHB's current valuation given the order dynamics, or whether the post-rally environment calls for structural profit-taking. The stock has gained 94 percent since the start of the year, a move that invites digestion periods as a matter of course.

The bull case rests on the translation of record orders into revenue and margin. If the second half mirrors the first, OHB will have demonstrated that its ambitious guidance is achievable, and the current pullback would be viewed as a healthy pause rather than a turning point.

The bear case centers on the possibility that much of the good news was already priced in when the stock peaked in the spring. If every positive announcement continues to be met with selling, that would suggest a longer consolidation lies ahead — one in which investors use strength to exit rather than enter.

The near-term catalyst calendar includes further concretization of the IRIS² contract and potential additional analyst coverage or price-target revisions. Until then, OHB remains a stock for investors with a tolerance for exceptional volatility — and a willingness to look past the daily tape to the structural transformation underneath.